Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform

PartnershipCD7-Targeted Lentiviral In Vivo CAR-TPositive

AI Analysis

Summary

Tempest Therapeutics secured an exclusive option to license a clinical-stage CD7-targeted lentiviral in vivo CAR-T platform, expanding its pipeline with a potentially significant cell therapy asset.

Importance:6/10

Sentiment:

0.60

licensingCAR-TCD7in vivolentiviralpartnership

Related Companies

$TPST

Read the original article

Published by yahoo_finance on September 15, 2026 8:05 PM

Read Original